Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), has announced its participation in Citi's 2025 Virtual Oncology Leadership Summit. Bill Lundberg, M.D., President and Chief Executive Officer of Merus, will deliver a presentation on Thursday, February 20, 2025, at 9:00 a.m. ET.
The presentation will be accessible via webcast on the Investors section of the company's website both during and after the event for a time.
Merus N.V. (Nasdaq: MRUS), una compagnia oncologica in fase clinica specializzata in anticorpi multispecifici innovativi di lunghezza completa (Biclonics® e Triclonics®), ha annunciato la sua partecipazione al Citi's 2025 Virtual Oncology Leadership Summit. Bill Lundberg, M.D., Presidente e Amministratore Delegato di Merus, presenterà un intervento giovedì 20 febbraio 2025, alle 9:00 ET.
L'intervento sarà accessibile tramite webcast nella sezione Investitori del sito web dell'azienda sia durante che dopo l'evento per un periodo di tempo.
Merus N.V. (Nasdaq: MRUS), una empresa de oncología en etapa clínica que se especializa en anticuerpos multispecíficos innovadores de longitud completa (Biclonics® y Triclonics®), ha anunciado su participación en el Citi's 2025 Virtual Oncology Leadership Summit. Bill Lundberg, M.D., Presidente y Director Ejecutivo de Merus, realizará una presentación el jueves 20 de febrero de 2025, a las 9:00 a.m. ET.
La presentación estará disponible a través de un webcast en la sección de Inversores del sitio web de la empresa, tanto durante como después del evento por un tiempo limitado.
Merus N.V. (Nasdaq: MRUS), 혁신적인 전체 길이 다중 특이성 항체(Biclonics® 및 Triclonics®)를 전문으로 하는 임상 단계의 종양학 회사가 Citi의 2025 가상 종양학 리더십 서밋에 참여한다고 발표했습니다. Bill Lundberg, M.D., Merus의 회장 겸 CEO가 2025년 2월 20일 목요일 오전 9시(ET)에 발표를 진행할 예정입니다.
이 발표는 이벤트 중 및 이후에 회사 웹사이트의 투자자 섹션을 통해 웹캐스트로 접근할 수 있습니다.
Merus N.V. (Nasdaq: MRUS), une entreprise de cancérologie en phase clinique spécialisée dans les anticorps multispecifiques innovants de longueur complète (Biclonics® et Triclonics®), a annoncé sa participation au Citi's 2025 Virtual Oncology Leadership Summit. Bill Lundberg, M.D., Président et Directeur Général de Merus, fera une présentation le jeudi 20 février 2025, à 9h00 ET.
La présentation sera accessible par webcast dans la section Investisseurs du site web de l'entreprise, à la fois pendant et après l'événement pendant une durée limitée.
Merus N.V. (Nasdaq: MRUS), ein klinisches Onkologieunternehmen, das sich auf innovative, vollwertige multispezifische Antikörper (Biclonics® und Triclonics®) spezialisiert hat, hat seine Teilnahme am Citi's 2025 Virtual Oncology Leadership Summit bekannt gegeben. Bill Lundberg, M.D., Präsident und CEO von Merus, wird am Donnerstag, den 20. Februar 2025, um 9:00 Uhr ET eine Präsentation halten.
Die Präsentation wird während und nach der Veranstaltung über einen Webcast im Bereich Investoren der Unternehmenswebsite zugänglich sein.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will present at Citi's 2025 Virtual Oncology Leadership Summit on Thursday, February 20, 2025 at 9:00 a.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
FAQ
When is Merus (MRUS) presenting at Citi's 2025 Virtual Oncology Leadership Summit?
How can investors watch Merus's (MRUS) presentation at the Citi Oncology Summit 2025?
What type of antibody technology does Merus (MRUS) develop?
Who will represent Merus (MRUS) at the Citi 2025 Virtual Oncology Leadership Summit?
